USD 5.4 billion
Report ID: SQSG30B2035 | Region: Global | Published Date: April, 2023 | Pages: 165 | Tables: 118 | Figures: 77
General Anesthesia Drugs Market size was valued at USD 5.4 billion in 2021 and is poised to grow from USD 5.59 billion in 2022 to USD 7.7 billion by 2030, growing at a CAGR of 3.5% in the forecast period (2023-2030).
General anaesthesia is a state of unconsciousness caused by the use of anaesthetic medications. The fundamental goal of general anaesthesia is to produce unconsciousness, analgesia, and lack of autonomic nervous system responses (ANS). IV anaesthetics are general anaesthetics that are delivered intravenously and are used for induction and short-term surgery to ease anxiety and produce amnesia. IV medications are commonly utilised in operations for cardiovascular disease (CVD) and chronic renal disease (CRD). The increased number of operations and new anaesthetic medication approvals are the key factors driving the growth of this market. According to the American Society of Plastic Surgeons, in the United States in 2020, 2.3 million cosmetic surgical treatments, 13.2 million cosmetic minimally invasive procedures, and 6.8 million reconstructive procedures will be performed, marking a 3% increase over 2019. This shows an increase in the number of procedures, which leads to an increase in the demand for anaesthetic medicines.
Furthermore, a startling 310 million major operations are conducted globally each year, according to the article 'Trauma of Major Surgery' published in the National Centre for Biotechnology Information (NCBI) in July 2020. Similarly, according to the article titled 'Incidence and Cumulative Risk of Major Surgery in Older Persons in the United States', which was published in July 2021, in the United States, nearly nine major surgeries were carried out annually for every 100 older persons, and more than one in every seven Medicare recipients underwent a major surgery over five years, portraying nearly 5 million unique older people.
Furthermore, the development and approval of innovative local anaesthetic medications is proving to be a new source of revenue for market participants. For example, in February 2021, PainPass announced the first Cannabidiol (CBD)/lidocaine product line aimed for treating chronic pain and externally numbing muscles. Hikma Pharmaceuticals PLC (Hikma) introduced Bupivacaine HCl Injection, USP in December 2021 through its US subsidiary, Hikma Pharmaceuticals United States Inc. The business has introduced 0.25%, 0.5%, and 0.75% concentrations in 10mL and 30mL dosages. Furthermore, PAION AG got permission from the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) in June 2021 for Byfavo (remimazolam besylate) in adults for procedural sedation. As a result, all the aforementioned factors, such as the rising number of surgical operations and product introductions, will drive the market throughout the projection period.
US General Anesthesia Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 5.4 billion
To get more reports on the above market click here to Buy The Report
The Global General Anesthesia Drugs market is segmented based on Type of Drug, Surgery Type, End-User, Route of Administration, and Region. Based on Type of Drug the market is segmented into Propofol, Sevoflurane, Desflurane, Others. Based on End-User the market is segmented into Hospital, Ambulatory surgical centres. Based on Surgery Type the market is segmented into Knee and hip replacements, Heart surgeries, Cancer surgery, General surgery. Based on Route of Administration the market us segmented into Intravenous, Inhalation. Based on region the global General Anesthesia Drugs market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.
General Anesthesia Drugs Market Analysis by Route of Administration
In 2021, the intravenous drugs segment is anticipated to hold the largest market share. Intravenous has a 63.3% revenue share in 2021 and is predicted to expand gradually over the projection period, with a CAGR of 3.9% by 2028. An intravenous method is used to deliver the medications directly to the systemic circulation. When rapid absorption is essential, IV injections are used, which include injecting medicine into veins using a needle.
General intravenous anaesthetic medicines are less costly and do not necessitate the use of pricey devices. Furthermore, intravenous anaesthetic medicines reduce cardiovascular depression and improve postoperative analgesia. These reasons are projected to drive this segment's growth over the forecast period.
To get detailed analysis on other segments, Request For Sample Report
North America currently dominates the anaesthetic drugs industry and is anticipated to maintain its dominance over the forecast year. The United States has the world's largest regional market. With the introduction of COVID-19, the United States experienced severe shortages of critical anaesthetic medicines, including midazolam, dexmedetomidine, propofol, and neuromuscular blocking agents. As a result, numerous corporations are increasing their anaesthetic medication manufacturing. For instance, Hikma Pharmaceutical introduced a brand-new medicine, "Propofol Injectable Emulsion," in the United States. Furthermore, this market is being pushed by an increase in the number of operations, an ageing population with an increase in chronic illnesses, and developments in anaesthetic technology.
According to the American Society of Plastic Surgeons (ASPS), about 768,000 total cosmetic treatments were performed in persons aged 10-29 years in 2020, and 6.1 million total cosmetic procedures were performed in people aged 40-54 years. These numbers show that surgical operations are rising in the region, which drives the need for anaesthetic medicines. The use of anaesthetics in general surgery is likely to contribute considerably to market growth. Furthermore, new anaesthetic medications are being developed in the nation, which is projected to drive market expansion. For example, in June 2020, Medova and the New York School of Regional Anesthesia (NYSORA) announced a collaboration to launch SAFIRA (SAFer Injection for Regional Anesthesia) in the United States. In addition, the Food and Drug Administration accepted a new drug application for cocaine hydrochloride (HCI; NUMBRINO) nasal solution 4% (40 mg/mL) made by Lannett Company for anaesthetic use in the United States in January 2020. Furthermore, Hikma Pharmaceuticals PLC (Hikma) introduced Bupivacaine HCl Injection USP in December 2021 via its US subsidiary Hikma Pharmaceuticals USA Inc. The business released 0.25%, 0.5%, and 0.75% in 10 millilitre and 30 millilitre dosages. Similarly, Blue-Zone Technologies Ltd got clearance from Health Canada in April 2020 for desflurane, USP, an anaesthetic medication used for general anaesthesia.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
General Anesthesia Drugs Market Driver
In recent decades, cancer has become much more common in the United States. The National Cancer Institute estimates that there are 16.9 million cancer survivors in the United States. The number of cancer survivors is expected to reach 22.2 million by 2030. The most common cancers are lung and bronchus cancer, breast cancer, prostate cancer, melanoma of the skin, colon and rectum cancer, bladder cancer, non-Hodgkin lymphoma, endometrial cancer, leukemia, kidney and renal pelvic cancer, pancreatic cancer, thyroid cancer, and liver cancer (listed in descending order based on estimated new cases in 2020). Prostate, lung, and colorectal cancers will account for 43% of all cancers diagnosed in men by 2020. Breast, lung, and colorectal cancer, on the other hand, accounted for more than half of all new malignancies diagnosed in women in 2020. Because cancer surgery offers the best chance of curing many tumors, particularly if the cancer is contained, the increased prevalence of cancer will result in an increase in the number of procedures. Because general anaesthesia is frequently used for surgical operations to treat cancer, the US general anaesthesia market will grow as the prevalence of cancer rises.
General Anesthesia Drugs Market Restraint
The use of pharmacologic agents, particularly general anaesthetic medicines, in paediatric patients necessitates extra caution. Infants and young children respond differently to anaesthetic medicines than adults due to a variety of characteristics such as body composition, protein binding, body temperature, cardiac output distribution, and functional maturity of the liver and kidneys. Various investigations have found that using general anaesthetics and sedative medicines in pregnant and young animals for more than 3 hours caused extensive nerve cell death in the brain. Recent human research indicates that a single, brief exposure to general anaesthetics and sedative medicines in new-borns or toddlers is unlikely to have a harmful impact on behaviour or learning. Considering this, the US Food and Drug Administration issued additional cautions about the use of general anaesthetics and sedative medicines in young children and pregnant women. Patients requiring surgery or other unpleasant and stressful treatments, including small children and pregnant women, require general anaesthetics and sedative medicines. The US Food and Drug Administration has issued a warning concerning the repeated or prolonged use of general anaesthetics and sedative medicines during operations or procedures in children under the age of three and pregnant women. The possible danger connected with the use of general anaesthetic medications in young children and pregnant women may cause a decline in the adoption of general anaesthetics by healthcare providers, stifling market growth.
Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report
The global market for general anaesthesia drugs is extremely fragmented, with multiple rivals in the development of general anaesthetic drugs. These firms are employing techniques such as mergers and acquisitions, partnerships and collaborations, and new product releases to match consumer demand and increase their client base. Furthermore, firms operating in the market are obtaining favourable findings for the potential effect of chemicals such as general anaesthesia, which might raise market growth even further. For instance, In June 2021, PAION AG, a speciality pharmaceutical firm, received favourable findings in the European Phase III trial for Remimazolam. It is an ultra-short-acting intravenous benzodiazepine sedative/anesthetic that is licenced for procedural sedation in the United States, Europe, and China, as well as general anaesthesia in South Korea and Japan. By the end of 2021, PAION AG intends to file an extension modification to the Marketing Authorization for remimazolam as general anaesthesia. As a result, the company's actions will broaden the market perspective in numerous areas, adding to market growth.
General Anesthesia Drugs Market Top Player's Company Profiles
General Anesthesia Drugs Market Recent Development
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information End-Users team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our analysis, we found that North America dominates the anaesthetic drugs industry and is expected to continue its dominance over the forecast year. US has world's largest regional market. COVID-19 caused serious shortages of midazolam, dexmedetomidine, propofol, and neuromuscular blocking drugs. Many companies are growing anaesthetic drug production. Researchers are focusing on anaesthetic medication research and development, which will drive market expansion throughout the predicted period.
|Market size value in 2021||USD 5.4 billion|
|Market size value in 2030||USD 5.59 billion|
|Forecast Unit (Value)||USD Billion|
|Regions covered||North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)|
Free report customization with purchase. Customization includes:-
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Parent Market Analysis
KEY MARKET INSIGHTS
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Global General Anesthesia Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global General Anesthesia Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global General Anesthesia Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global General Anesthesia Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Our industry expert will work with you to provide you with customized data in a short amount of time.SPEAK TO AN ANALYST
Get lifetime access to our reportsBasic Plan $5,000 Team Plan $10,000 SUBSCRIBE NOW
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "
- Mr. Ali Zali, Commercial Director, ICIIC Iran.
Product ID: SQSG30B2035